In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients

• Главные авторы: Elena M. Tosca (Автор), Alessandro De Carlo (Автор), Roberta Bartolucci (Автор), Francesco Fiorentini (Автор), Silvia Di Tollo (Автор), Maurizio Caserini (Автор), Maurizio Rocchetti (Автор), Paolo Bettica (Автор), Paolo Magni (Автор)
• Формат: ‌
• Опубликовано: Wiley, 2024-03-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by excessive levels of platelets (PLT), white blood cells (WBC), and hematocrit (HCT). Givinostat (ITF2357) is a potent histone‐deacetylase inhibitor that showed a good safety/efficacy profile in PV patients durin...